Apothecon Pharma appoints Shyamakant Giri as Group CEO

In his new role, he will lead the growth strategy for the group’s operations, including Apothecon Pharmaceuticals in India and Navinta LLC in the United States

Regeneron signs $2.32 billion deal with Parabilis for Helicon conjugates

The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform

IGI’s new drug candidate ISB 2301 to target solid tumors

The company intends to file an IND submission by the end of this year and begin clinical studies in 2027

MedGenome to expand integrated diagnostics access across Mumbai suburbs

Collaboration with Siddhi Diagnostics combines genomics and advanced imaging capabilities to strengthen precision diagnostics in high-growth suburban markets

FDA grants accelerated approval to BEQALZI for relapsed mantle cell lymphoma

ParexelAI launched to accelerate clinical development and improve trial efficiency

The platform combines internally developed technologies, strategic partnerships, and external AI capabilities

Dr. Reddy’s launches generic semaglutide in Canada

Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada

Neuland Laboratories posts blockbuster FY26 performance

Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI

The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy

Gilead posts solid Q1 2026 growth & raises full-year outlook on HIV momentum